









Markets
/
Stocks
/
nasdaq-uncy
/

Unicycive Therapeutics Inc

UNCY

6.690USD

+0.500+8.08%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

139.49MMarket Cap

LossP/E TTM



Unicycive Therapeutics Inc

6.690

+0.500+8.08%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Unicycive Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Unicycive Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 131 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 46.50.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Unicycive Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

131 / 392

Overall Ranking

269 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Unicycive Therapeutics Inc Highlights

StrengthsRisks

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -1.92, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 6.67M shares, decreasing 3.66% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 788.59K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.79.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

46.500

Target Price

+614.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Unicycive Therapeutics Inc is 3.94, ranking 391 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

3.94

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

0.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

0.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.00

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Unicycive Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Unicycive Therapeutics Inc is 7.33, ranking 137 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.92, which is -901.89% below the recent high of 15.42 and -7.62% above the recent low of -2.07.

Score

Industry at a Glance

Previous score

7.33

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 131/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Unicycive Therapeutics Inc is 8.25, ranking 147 out of 392 in the Biotechnology & Medical Research industry. The average price target is 43.00, with a high of 90.00 and a low of 21.00.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

46.500

Target Price

+614.29%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Unicycive Therapeutics Inc

UNCY

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Unicycive Therapeutics Inc is 9.07, ranking 40 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.44 and the support level at 5.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.23

Change

1.84

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.098

Neutral

RSI(14)

53.438

Neutral

STOCH(KDJ)(9,3,3)

48.634

Neutral

ATR(14)

0.554

Low Volatility

CCI(14)

-18.289

Neutral

Williams %R

41.096

Buy

TRIX(12,20)

0.442

Sell

StochRSI(14)

62.890

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

6.552

Buy

MA10

6.650

Buy

MA20

6.544

Buy

MA50

6.211

Buy

MA100

5.458

Buy

MA200

5.402

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Unicycive Therapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 31.03%, representing a quarter-over-quarter decrease of 1.13%. The largest institutional shareholder is The Vanguard, holding a total of 788.59K shares, representing 3.67% of shares outstanding, with 262.40% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Vivo Capital, LLC

1.79M

+57.42%

Octagon Capital Advisors LP

1.00M

Nantahala Capital Management, LLC

939.20K

Great Point Partners, LLC

796.56K

The Vanguard Group, Inc.

Star Investors

658.88K

+8.73%

Gupta (Shalabh K)

597.25K

-0.02%

Logos Global Management LP

473.56K

+0.00%

Rosalind Advisors, Inc.

242.49K

Geode Capital Management, L.L.C.

125.73K

+113.87%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Unicycive Therapeutics Inc is 3.80, ranking 120 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.84. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.